ClinicalTrials.gg
CompletedNCT00452907Updated Feb 17, 2010

ACT MALI: Treatment of Malaria Based on Combination Therapies

A Phase 4 interventional study of Artesunate and Artesunate + Sulfadoxine-Pyrimethamine in Malaria, sponsored by Sanofi. Completed at 1 site in Mali. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2010-02-17.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies testing artesunate in Malaria — none open to participants now, none under way, none of them phase 3. Artesunate · Malaria.

Enrollment
14th of 66
780 · median 290
Started
2005
with 5 others
Phase 4
27 of 68
none open now
Registered
24th of 68
by date
Lead sponsor
6 of 68
Sanofi

Among the 68 studies testing artesunate in Malaria, this one is the 14th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2005, is one of 27 in phase 4, and was the 24th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

None of the 68 studies testing artesunate in Malaria is open now. The open studies under Malaria, anywhere →

About artesunate

Artesunate: first FDA approval 2020 (ARTESUNATE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 68 studies testing artesunate in Malaria as a file.
02

Study summary

Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated falciparum malaria and malaria attributable anemia

03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight > 5kg
  • Residence in the investigator site area for the duration of the trial
  • Axillary temperature ≥ 37,5°C at Day 0
  • Confirmed Plasmodium falciparum infection,with parasitemia range from 2000 to 200000 asexual parasites /µl of blood

Exclusion criteria

Exclusion Criteria:

  • Danger signs or signs of severe malaria
  • Other severe illnesses
  • Allergy to one of the drugs
  • Pregnant women

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
780 participants (actual)

Study arms

  • Experimental
    1

    Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment

    Drug: Artesunate

  • Active comparator
    2

    Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os

    Drug: Artesunate + Sulfadoxine-Pyrimethamine

  • Active comparator
    3

    Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days

    Drug: arthemether + lumefantrine

Interventions

  • oad, per os, 3 days of treatment

  • DrugArtesunate + Sulfadoxine-Pyrimethamine

    Drug page: Artesunate

    oad, per os

  • Drugarthemether + lumefantrine

    bid, per os. Duration of treatment: 3 days

06

What researchers measure

Primary outcomes

  1. Clinical and parasitological cure rate

    Time frame: at day 28

  2. Clinical and biological tolerability

    Time frame: During the study period

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bougoula, Mali
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2007
First posted
Mar 28, 2007
Start
Jul 2005
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Last update
Feb 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00452907
Lead sponsor
Sanofi
First posted
Mar 28, 2007
Start date
Jul 2005
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Feb 17, 2010

Study contacts

Valérie Lameyre
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artesunate

Start the discussion